|
| | 100TH GENERAL ASSEMBLY
State of Illinois
2017 and 2018 HB4142 Introduced 10/26/2017, by Rep. Mark Batinick - Daniel Swanson - Laura Fine - Silvana Tabares SYNOPSIS AS INTRODUCED: |
| |
Amends the Newborn Metabolic Screening Act. Requires the Department of Public Health to provide all newborns and infants within 12 months of birth with screening tests for the presence of spinal muscular atrophy. Provides that the testing shall begin within 12 months of the occurrence of specified events. Provides that the Department is authorized to implement an additional fee for the screening prior to beginning the testing in order to accumulate the resources for start-up and other costs associated with implementation of the screening and thereafter to support the costs associated with screening and follow-up programs for spinal muscular atrophy.
|
| |
| | | FISCAL NOTE ACT MAY APPLY | |
| | A BILL FOR |
|
|
| | HB4142 | | LRB100 14281 MJP 29055 b |
|
|
1 | | AN ACT concerning health.
|
2 | | Be it enacted by the People of the State of Illinois,
|
3 | | represented in the General Assembly:
|
4 | | Section 5. The Newborn Metabolic Screening Act is amended |
5 | | by adding Section 3.35 as follows: |
6 | | (410 ILCS 240/3.35 new) |
7 | | Sec. 3.35. Spinal muscular atrophy. In accordance with the |
8 | | timetable specified in this Section, the Department shall |
9 | | provide all newborns and infants within 12 months of birth with |
10 | | screening tests for the presence of spinal muscular atrophy. |
11 | | The testing shall begin within 12 months following the |
12 | | occurrence of all of the following: |
13 | | (1) the establishment and verification of relevant and |
14 | | appropriate performance specifications as defined under |
15 | | the federal Clinical Laboratory Improvement Amendments and |
16 | | regulations thereunder for Federal Drug |
17 | | Administration-cleared or in-house developed methods, |
18 | | performed under an institutional review board approved |
19 | | protocol, if required; |
20 | | (2) the availability of quality assurance testing and |
21 | | comparative threshold values for the spinal muscular |
22 | | atrophy screening test; |
23 | | (3) the acquisition and installment by the Department |